Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 28/06/2024 BST			5-day change	1st Jan Change
1,006 ^DKK	+0.30%		+1.79%	+44.05%

06-28	India plans incentives for diabetes, obesity drug makers in 2026, government official says	RE
06-28	NOVO NORDISK : UBS gives a Neutral rating	ZD

NOVO NORDISK : Goldman Sachs reiterates its Buy rating

June 27, 2024 at 07:45 am

James Quigley from Goldman Sachs retains his positive opinion on the stock with a Buy rating. No major update to the target price set at DKK 1075 compared to DKK 1070.

Latest news about Novo Nordisk A/S

India plans incentives for diabetes, obesity drug makers in 2026, government official says	06-28	RE
NOVO NORDISK : UBS gives a Neutral rating	06-28	ZD
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	06-27	MT
Top Midday Stories: Walgreens Shares Tumble on Lower Guidance, Store Closures; SM Energy, NOG to Buy XCL Resources; Uber, Lyft Worker Classification Heads to Massachusetts Ballot	06-27	MT
Novo Nordisk to Limit Launch of Wegovy in China, Executive Says	06-27	MT
NOVO NORDISK : JP Morgan gives a Buy rating	06-27	ZD
The same old winners	06-27
NOVO NORDISK : Goldman Sachs reiterates its Buy rating	06-27	ZD
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	06-26	MT
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million	06-26	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	06-26	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	06-26	MT
Sector Update: Health Care	06-26	MT
European Equities Close Lower in Wednesday Trading	06-26	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	06-26	MT
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial	06-26	MT
Novo Nordisk Halts Late-stage Hypertension, Kidney Disease Treatment Trial; DKK6 Billion Impairment Loss Expected	06-26	MT
Novo Nordisk: trial failure and impact on results	06-26	CF
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial	06-26	MT
Novo Nordisk to Take $816 Million Impairment Charge After Stopping Clarion-CKD Trial	06-26	MT
Novo Nordisk makes impairment loss of $816 million in Q2	06-26	RE
AlphaValue/Baader Europe Downgrades Novo Nordisk to Add from Buy, Raises PT	06-26	MT
China Approves Novo Nordisk's Injection for Long-term Weight Management	06-26	MT
Health Care Up as Novo Nordisk Gets China OK -- Health Care Roundup	06-25	DJ
Trending : Novo Nordisk's Wegovy Weight-Loss Drug Gets Chinese Approval	06-25	DJ

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 05:36 pm

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 05:09 pm

Novo Nordisk doesn't disappoint

January 31, 2024 at 03:48 pm

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,006 DKK

Average target price

949.7 DKK

Spread / Average Target

-5.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+44.05%	641B
ELI LILLY AND COMPANY	+55.32%	815B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B
SANOFI	+0.20%	120B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Goldman Sachs reiterates its Buy rating

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals